

Francisco M Marty

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4171487/publications.pdf>

Version: 2024-02-01

267
papers

15,604
citations

22099

59
h-index

19690

117
g-index

276
all docs

276
docs citations

276
times ranked

17163
citing authors

#	ARTICLE	IF	CITATIONS
1	Cell-free DNA profiling informs all major complications of hematopoietic cell transplantation. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	16
2	Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. New England Journal of Medicine, 2022, 386, 305-315.	13.9	813
3	Epidemiology and outcomes of invasive aspergillosis among pediatric immunocompromised patients: A 12-year single-center experience. Medical Mycology, 2022, 60, .	0.3	2
4	Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial. Clinical Infectious Diseases, 2022, 75, 690-701.	2.9	97
5	Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax. Leukemia and Lymphoma, 2022, 63, 1934-1941.	0.6	13
6	Cytomegalovirus-related Complications and Management in Facial Vascularized Composite Allotransplantation: An International Multicenter Retrospective Cohort Study. Transplantation, 2022, 106, 2031-2043.	0.5	5
7	Clarithromycinâ€“Rifampin-Based Treatment for Nontuberculous Mycobacteria Infections in Immunocompromised Patients who Require Concomitant CYP-Metabolized Medications. Open Forum Infectious Diseases, 2022, 9, ofab582.	0.4	0
8	Hepatitis B Virus Vaccination after Allogeneic Hematopoietic Cell Transplantation Prevents Post-Transplantation Hepatitis B Virus Reactivation. Transplantation and Cellular Therapy, 2022, 28, 402.e1-402.e5.	0.6	3
9	Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma. Blood Advances, 2022, 6, 4821-4830.	2.5	20
10	Pathologies of oral and sinonasal mucosa following facial vascularized composite allotransplantation. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2021, 74, 1562-1571.	0.5	13
11	Development of a Set of Lupusâ€“Specific, Ambulatory Careâ€“Sensitive, Potentially Preventable Adverse Conditions: A Delphi Consensus Study. Arthritis Care and Research, 2021, 73, 146-157.	1.5	15
12	DAS181 Treatment of Severe Lower Respiratory Tract Parainfluenza Virus Infection in Immunocompromised Patients: A Phase 2 Randomized, Placebo-Controlled Study. Clinical Infectious Diseases, 2021, 73, e773-e781.	2.9	17
13	Cell-free DNA tissues of origin by methylation profiling reveals significant cell, tissue, and organ-specific injury related to COVID-19 severity. Med, 2021, 2, 411-422.e5.	2.2	41
14	Isavuconazole Treatment of Invasive Fungal Sinusitis: A Post Hoc Analysis of the SECURE and VITAL Trials. Clinical Infectious Diseases, 2021, 73, e1380-e1383.	2.9	5
15	Cytomegalovirus events in highâ€“risk allogeneic hematopoieticâ€“cell transplantation patients who received letermovir prophylaxis. Transplant Infectious Disease, 2021, 23, e13619.	0.7	8
16	Full facial retransplantation in a female patientâ€“Technical, immunologic, and clinical considerations. American Journal of Transplantation, 2021, 21, 3472-3480.	2.6	21
17	Osmotic Tubulopathy in a Patient With COVID-19 Treated With Remdesivir. Kidney International Reports, 2021, 6, 1987-1991.	0.4	4
18	Impact of Changes of the 2020 Consensus Definitions of Invasive Aspergillosis on Clinical Trial Design: Unintended Consequences for Prevention Trials?. Open Forum Infectious Diseases, 2021, 8, ofab441.	0.4	3

#	ARTICLE	IF	CITATIONS
19	Triazole antifungal use for prophylaxis and treatment of invasive fungal diseases for patients receiving gilteritinib. <i>Leukemia Research</i> , 2021, 108, 106610.	0.4	6
20	American Society for Transplantation and Cellular Therapy Series: "Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 707-719.	0.6	45
21	When to change treatment of acute invasive aspergillosis: an expert viewpoint. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 77, 16-23.	1.3	15
22	Somatic GATA2 mutations define a subgroup of myeloid malignancy patients at high risk for invasive fungal disease. <i>Blood Advances</i> , 2021, 5, 54-60.	2.5	11
23	186. Evaluating Clinical Outcomes for Treatment of Staphylococcal Bloodstream Infection in Patients with Febrile Neutropenia. <i>Open Forum Infectious Diseases</i> , 2021, 8, S201-S201.	0.4	0
24	711. A Unique Breath Secondary Metabolite Volatile Signature for the Diagnosis of Histoplasmosis. <i>Open Forum Infectious Diseases</i> , 2021, 8, S454-S455.	0.4	0
25	992. Oral Ibrexafungerp Outcomes in Patients with Oropharyngeal and Esophageal Candidiasis from an Interim Analysis of a Phase 3 Open-label Study (FURI). <i>Open Forum Infectious Diseases</i> , 2021, 8, S586-S587.	0.4	0
26	1399. Clarithromycin-Rifampin-based Treatment for Non-tuberculous Mycobacterial Infections in Immunocompromised Patients Who Require Concomitant CYP-Metabolized Medications. <i>Open Forum Infectious Diseases</i> , 2021, 8, S784-S784.	0.4	0
27	123. Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI). <i>Open Forum Infectious Diseases</i> , 2021, 8, S73-S74.	0.4	2
28	Reply to Aronson et al. <i>Clinical Infectious Diseases</i> , 2020, 70, 1262.	2.9	0
29	A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2020, 70, 1525-1533.	2.9	100
30	Long-term risk of hepatocellular carcinoma mortality in 23220 hospitalized patients treated with micafungin or other parenteral antifungals. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 221-228.	1.3	6
31	Long-term Persistence of an Extensively Drug-Resistant Subclade of Globally Distributed <i>Pseudomonas aeruginosa</i> Clonal Complex 446 in an Academic Medical Center. <i>Clinical Infectious Diseases</i> , 2020, 71, 1524-1531.	2.9	20
32	Reply to Singh. <i>Clinical Infectious Diseases</i> , 2020, 71, 471-472.	2.9	3
33	Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system. <i>Medical Mycology</i> , 2020, 58, 417-424.	0.3	48
34	Use of triazoles for the treatment of invasive aspergillosis: A three-year cohort analysis. <i>Mycoses</i> , 2020, 63, 58-64.	1.8	9
35	A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Lower Respiratory Tract. <i>Clinical Infectious Diseases</i> , 2020, 71, 2787-2795.	2.9	44
36	A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2020, 71, 2777-2786.	2.9	53

#	ARTICLE	IF	CITATIONS
37	Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation. American Journal of Transplantation, 2020, 20, 1703-1711.	2.6	42
38	Omadacycline for the Treatment of Mycobacterium abscessus Disease: A Case Series. Open Forum Infectious Diseases, 2020, 7, ofaa415.	0.4	33
39	Oral brincidofovir decreases the incidence of HHV-6B viremia after allogeneic HCT. Blood, 2020, 135, 1447-1451.	0.6	15
40	Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19. JAMA - Journal of the American Medical Association, 2020, 324, 1048.	3.8	1,032
41	Racial Disproportionality in Covid Clinical Trials. New England Journal of Medicine, 2020, 383, 2486-2490.	13.9	20
42	New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19. Antimicrobial Agents and Chemotherapy, 2020, 65, .	1.4	59
43	BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation. Blood Advances, 2020, 4, 1881-1893.	2.5	16
44	How to Obtain a Nasopharyngeal Swab Specimen. New England Journal of Medicine, 2020, 383, e14.	13.9	86
45	Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. New England Journal of Medicine, 2020, 383, 1827-1837.	13.9	1,152
46	Missing the Target. New England Journal of Medicine, 2020, 382, 1353-1359.	13.9	0
47	Accelerated chronic skin changes without allograft vasculopathy: A 10-year outcome report after face transplantation. Surgery, 2020, 167, 991-998.	1.0	23
48	Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection. Lung Cancer, 2020, 145, 181-185.	0.9	36
49	Fulminant Acanthamoeba castellanii Encephalitis in an Ibrutinib-Treated Patient. Open Forum Infectious Diseases, 2020, 7, ofaa025.	0.4	3
50	Defibrotide formulations contain (1 α '3)- β -D-glucan that could influence clinical diagnostic testing. Bone Marrow Transplantation, 2020, 55, 2045-2046.	1.3	2
51	A CRISPR-based assay for the detection of opportunistic infections post-transplantation and for the monitoring of transplant rejection. Nature Biomedical Engineering, 2020, 4, 601-609.	11.6	80
52	How to Obtain a Nasopharyngeal Swab Specimen. New England Journal of Medicine, 2020, 382, e76.	13.9	199
53	1248. Efficacy and Safety of Oral Ibrexafungerp in 41 Patients with Refractory Fungal Diseases, Interim Analysis of a Phase 3 Open-label Study (FURI). Open Forum Infectious Diseases, 2020, 7, S642-S642.	0.4	5
54	Missing the Target. New England Journal of Medicine, 2020, 382, e23.	13.9	0

#	ARTICLE	IF	CITATIONS
55	195. Economic and Clinical Burden of Respiratory Virus Infections in Allogeneic Hematopoietic Cell Transplantation Recipients. <i>Open Forum Infectious Diseases</i> , 2020, 7, S226-S226.	0.4	0
56	72. Remdesivir vs Standard Care in Patients with Moderate covid-19. <i>Open Forum Infectious Diseases</i> , 2020, 7, S166-S167.	0.4	1
57	Isavuconazole for the treatment of invasive fungal disease in patients receiving ibrutinib. <i>Leukemia and Lymphoma</i> , 2019, 60, 527-530.	0.6	14
58	Reactivation of BK virus after double umbilical cord blood transplantation in adults correlates with impaired reconstitution of CD4+ and CD8+ T effector memory cells and increase of T regulatory cells. <i>Clinical Immunology</i> , 2019, 207, 18-23.	1.4	10
59	Case 31-2019: A 45-Year-Old Woman with Headache and Somnolence. <i>New England Journal of Medicine</i> , 2019, 381, 1459-1470.	13.9	5
60	Herpes Zoster Subunit Vaccination for Renal Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2019, 70, 718-719.	2.9	2
61	Invasive Fungal Carotiditis: A Rare Manifestation of Cranial Invasive Fungal Disease: Case Series and Systematic Review of the Literature. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz392.	0.4	9
62	Draft Genome Sequence of <i>Pseudomonas aeruginosa</i> Strain BWH047, a Sequence Type 235 Multidrug-Resistant Clinical Isolate Expressing High Levels of Colistin Resistance. <i>Microbiology Resource Announcements</i> , 2019, 8, .	0.3	1
63	Risk of Latent Tuberculosis Reactivation After Hematopoietic cell Transplantation. <i>Clinical Infectious Diseases</i> , 2019, 69, 869-872.	2.9	22
64	Five-Year Follow-up after Face Transplantation. <i>New England Journal of Medicine</i> , 2019, 380, 2579-2581.	13.9	46
65	A Post-Hoc Analysis of the Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Trial to Examine the Effects of DAS181 in Hematopoietic Cell Transplant (HCT) Recipients with Parainfluenza Virus (PIV) Lower Respiratory Tract Infection (LRTI) on Supplemental Oxygen (SO). <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S75.	2.0	0
66	Outcomes of patients with invasive fusariosis who undergo further immunosuppressive treatments, is there a role for secondary prophylaxis?. <i>Mycoses</i> , 2019, 62, 413-417.	1.8	18
67	2453. Prolonged Local Epidemic of an XDR <i>P. aeruginosa</i> Subclade of High-Risk Clonal Complex 298. <i>Open Forum Infectious Diseases</i> , 2019, 6, S848-S848.	0.4	0
68	2596. Invasive Fungal Disease in Patients with GATA2 Variant Hematologic Malignancy. <i>Open Forum Infectious Diseases</i> , 2019, 6, S902-S902.	0.4	0
69	269. Epidemiology and Outcomes of Invasive Aspergillosis (IA) Among Pediatric Immunocompromised Patients: A 12-Year, Single-Center Experience. <i>Open Forum Infectious Diseases</i> , 2019, 6, S149-S149.	0.4	0
70	1024. Evaluation of Atovaquone Prescribing for <i>Pneumocystis jirovecii</i> Pneumonia (PJP) Prophylaxis. <i>Open Forum Infectious Diseases</i> , 2019, 6, S360-S361.	0.4	0
71	Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 1255-1264.	2.9	137
72	A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 369-381.	2.0	151

#	ARTICLE	IF	CITATIONS
73	Letermovir Prophylaxis for Cytomegalovirus. <i>New England Journal of Medicine</i> , 2018, 378, 963-965.	13.9	7
74	Risk of hepatitis B virus reactivation in patients treated with ibrutinib. <i>Blood</i> , 2018, 131, 1987-1989.	0.6	42
75	90-Day Risk of Bloodstream Infections with Enteric Pathogens (BSI-EP) in Patients with Gastrointestinal Graft-Versus-Host Disease (GI-GVHD). <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S375.	2.0	2
76	Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species. <i>Mycoses</i> , 2018, 61, 485-497.	1.8	24
77	Isavuconazole for treatment of rare invasive fungal diseases. <i>Mycoses</i> , 2018, 61, 518-533.	1.8	32
78	Eponychial lesions following bilateral upper extremity vascular composite allotransplantation: a case report. <i>Case Reports in Plastic Surgery & Hand Surgery</i> , 2018, 5, 14-17.	0.1	2
79	Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 942-945.	1.3	27
80	Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-“Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1037-1042.	0.5	83
81	Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial. <i>Mycoses</i> , 2018, 61, 420-429.	1.8	25
82	1715. A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Trial to Examine the Effects of DAS181 in Immunocompromised (IC) Patients With Parainfluenza Virus (PIV) Lower Respiratory Tract Infection (LRTI) on Supplemental Oxygen (SO). <i>Open Forum Infectious Diseases</i> , 2018, 5, S50-S51.	0.4	4
83	1140. GATA2 Mutations Are Frequently Identified Among Patients With Myeloid Malignancies Who Develop Invasive Aspergillosis. <i>Open Forum Infectious Diseases</i> , 2018, 5, S342-S342.	0.4	0
84	1576. Risk of Clinical Tuberculosis (TB) Among Patients with Latent TB Infection (LTBI) Who Undergo Allogeneic Hematopoietic-Cell Transplantation (HCT). <i>Open Forum Infectious Diseases</i> , 2018, 5, S492-S492.	0.4	0
85	1557. Acyclovir-Resistant (ACV-R) Herpes Simplex Virus (HSV) Disease in Patients with Hematologic Malignancies (HM) and Hematopoietic-Cell Transplant (HCT) Recipients. <i>Open Forum Infectious Diseases</i> , 2018, 5, S484-S484.	0.4	0
86	358. Comparison of Voriconazole (VORI), Isavuconazole (ISAV), and Posaconazole (POSA) in the Initial Treatment of Patients With Invasive Aspergillosis (IA). <i>Open Forum Infectious Diseases</i> , 2018, 5, S140-S141.	0.4	2
87	1730. Outcomes of Patients With Detectable Cytomegalovirus (CMV) DNA at Randomization in the Double-blind, Placebo-Controlled Phase 3 Trial of Letermovir (LET) Prophylaxis for CMV-Seropositive Allogeneic Hematopoietic-Cell Transplantation (HCT) Recipients. <i>Open Forum Infectious Diseases</i> , 2018, 5, S56-S57.	0.4	1
88	408. Invasive Fungal Petrositis and Carotiditis (IFPAC) Syndrome in Immunocompromised Hosts: An Unrecognized, Often Catastrophic Invasive Fungal Disease (IFD). <i>Open Forum Infectious Diseases</i> , 2018, 5, S156-S156.	0.4	0
89	Authors’™ Response. <i>Journal of Thoracic Oncology</i> , 2018, 13, e237.	0.5	0
90	1564. Lower Rates of Epstein-“Barr Virus (EBV) Viremia in Pediatric Solid Organ Transplant (SOT) Recipients Who Received Valganciclovir Prophylaxis. <i>Open Forum Infectious Diseases</i> , 2018, 5, S487-S488.	0.4	1

#	ARTICLE	IF	CITATIONS
91	Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2018, 2, 2159-2175.	2.5	89
92	Human Herpes Virus 8 in HIV-1 infected individuals receiving cancer chemotherapy and stem cell transplantation. <i>PLoS ONE</i> , 2018, 13, e0197298.	1.1	6
93	Safety and immunogenicity of conjugate quadrivalent meningococcal vaccination after hematopoietic cell transplantation. <i>Blood Advances</i> , 2018, 2, 1272-1276.	2.5	9
94	NK-cell activation is associated with increased HIV transcriptional activity following allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2018, 2, 1412-1416.	2.5	2
95	Cytomegalovirus Infection Among Cord Blood Allogeneic Transplantation Recipients: Low Incidence of Cytomegalovirus Events without High-Dose Valacyclovir Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2164-2165.	2.0	3
96	Case 5-2018: A Man with Confusion after Stem-Cell Transplantation. <i>New England Journal of Medicine</i> , 2018, 378, 2544-2545.	13.9	0
97	Inconsistent HIV reservoir dynamics and immune responses following anti-PD-1 therapy in cancer patients with HIV infection. <i>Annals of Oncology</i> , 2018, 29, 2141-2142.	0.6	47
98	Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2017, 5, 135-146.	5.2	85
99	Serious Infection Rates Among Children With Systemic Lupus Erythematosus Enrolled in Medicaid. <i>Arthritis Care and Research</i> , 2017, 69, 1620-1626.	1.5	34
100	The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline. <i>Oncologist</i> , 2017, 22, 343-350.	1.9	57
101	Post-Babesiosis Warm Autoimmune Hemolytic Anemia. <i>New England Journal of Medicine</i> , 2017, 376, 939-946.	13.9	40
102	Dasatinib Use and Risk of Cytomegalovirus Reactivation After Allogeneic Hematopoietic-Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2017, 65, 510-513.	2.9	22
103	Use of Multimodality Imaging in Diagnosing Invasive Fungal Diseases of the Heart. <i>Circulation: Cardiovascular Imaging</i> , 2017, 10, .	1.3	1
104	Human Immunodeficiency Virus Type 1 Persistence Following Systemic Chemotherapy for Malignancy. <i>Journal of Infectious Diseases</i> , 2017, 216, 254-262.	1.9	41
105	Maribavir for Treatment of Cytomegalovirus Infections Resistant or Refractory to Ganciclovir or Foscarnet in Hematopoietic Stem Cell Transplant or Solid Organ Transplant Recipients: A Randomized, Dose-Ranging, Double-Blind, Phase 2 Study. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S56-S57.	2.0	2
106	Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	52
107	Breath-Based Diagnosis of Invasive Mucormycosis (IM). <i>Open Forum Infectious Diseases</i> , 2017, 4, S53-S54.	0.4	20
108	Seasonal Variability Precipitating Hand Transplant Rejection?. <i>Transplantation</i> , 2017, 101, e313.	0.5	10

#	ARTICLE	IF	CITATIONS
109	Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. <i>New England Journal of Medicine</i> , 2017, 377, 2433-2444.	13.9	796
110	Oral health status and risk of bacteremia following allogeneic hematopoietic cell transplantation. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2017, 124, 253-260.	0.2	16
111	Comparative Rates of Serious Infections Among Patients With Systemic Lupus Erythematosus Receiving Immunosuppressive Medications. <i>Arthritis and Rheumatology</i> , 2017, 69, 387-397.	2.9	65
112	Opportunistic Infections (OIs) in Patients with Hematologic Malignancies (HM) Treated with Brutonâ€™s Tyrosine Kinase (BTK) and Phosphoinositide 3 Kinase (PI3K) Inhibitors: An 8-Year Retrospective Cohort Study. <i>Open Forum Infectious Diseases</i> , 2017, 4, S699-S699.	0.4	4
113	Mortality Analysis of the Cytomegalovirus (CMV) Infection Letermovir Prophylaxis Trial in CMV-Seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation (HCT). <i>Open Forum Infectious Diseases</i> , 2017, 4, S311-S311.	0.4	2
114	Adenovirus (ADV) Infection and Disease after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): Epidemiology and Predictors of Mortality. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
115	In Vitro Volatile Metabolite Signatures of Common Pathogenic <i>Fusarium</i> Species. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	1
116	Examining the In Vitro Volatile Metabolite Profile of Pathogenic <i>Scedosporium</i> and <i>Lomentospora</i> Species. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
117	Dasatinib Use May Be a Novel Risk Factor for Cytomegalovirus (CMV) Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	1
118	Donor CMV Serostatus and Dose Adjustments in CMV Prophylaxis Increase CMV Infection Risk after Lung Transplantation. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
119	Safety of Live-attenuated Zoster Vaccination in Multiple Myeloma Patients Receiving Maintenance Lenalidomide after Autologous Stem Cell Transplantation.. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
120	Safety of MMR Vaccination in Multiple Myeloma Patients Receiving Maintenance Lenalidomide or Bortezomib after Autologous Stem Cell Transplantation.. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
121	Safety of Foscarnet (FOS) Treatment for Human Herpesviruses (HHV) in a Contemporary Cohort of Immunocompromised Patients. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
122	Guillainâ€™BarrÃ© syndrome associated with resistant cytomegalovirus infection after face transplantation. <i>Transplant Infectious Disease</i> , 2016, 18, 288-292.	0.7	13
123	Brincidofovir for Prevention of Cytomegalovirus (CMV) after Allogeneic Hematopoietic Cell Transplantation (HCT) in CMV-Seropositive Patients: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S23.	2.0	34
124	Cytomegalovirus Reactivation Does Not Reduce the Risk of Disease Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S329.	2.0	0
125	The VITAL study: case control studies are hypothesis-generating â€” Authors' reply. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 886-887.	4.6	5
126	Introducing the Wiley Transplant Peer Review Network. <i>Transplant International</i> , 2016, 29, 839-841.	0.8	0

#	ARTICLE	IF	CITATIONS
127	Short-term risk of liver and renal injury in hospitalized patients using micafungin: a multicentre cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2938-2944.	1.3	15
128	Introducing the Wiley Transplant Peer Review Network. <i>American Journal of Transplantation</i> , 2016, 16, 2505-2507.	2.6	1
129	Maribavir for Treatment of Cytomegalovirus (CMV) Infections Resistant or Refractory to Ganciclovir or Foscarnet in Hematopoietic Stem Cell Transplant (SCT) or Solid Organ Transplant (SOT) Recipients: A Randomized, Dose-Ranging, Double-Blind, Phase 2 Study. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	7
130	Norovirus Infection in Transplantation: Prolonged and Morbid Diarrhea. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
131	Face Transplantation in a Highly Sensitized Recipient. <i>Military Medicine</i> , 2016, 181, 221-226.	0.4	11
132	Introducing The Wiley Transplant Peer Review Network. <i>Artificial Organs</i> , 2016, 40, 635-637.	1.0	0
133	Resolution of diarrhea in an immunocompromised patient with chronic norovirus gastroenteritis correlates with constitution of specific antibody blockade titer. <i>Infection</i> , 2016, 44, 551-554.	2.3	12
134	Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 828-837.	4.6	528
135	Utility of in-house fluconazole disk diffusion susceptibility testing in the treatment of candidemia. <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 84, 223-226.	0.8	0
136	Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 359-370.	2.0	127
137	BK Virus-Specific T Cell Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 3425-3425.	0.6	0
138	Cerebrospinal fluid <i>Coccidioides</i> antigen testing in the diagnosis and management of central nervous system coccidioidomycosis. <i>Mycoses</i> , 2015, 58, 598-602.	1.8	19
139	Utility of Sentinel Flaps in Assessing Facial Allograft Rejection. <i>Plastic and Reconstructive Surgery</i> , 2015, 135, 250-258.	0.7	39
140	Meta-Analysis and Cost Comparison of Empirical versus Pre-Emptive Antifungal Strategies in Hematologic Malignancy Patients with High-Risk Febrile Neutropenia. <i>PLoS ONE</i> , 2015, 10, e0140930.	1.1	46
141	Risk factors for invasive fungal disease in heart transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 227-232.	0.3	30
142	Initial Experience of Dual Maintenance Immunosuppression With Steroid Withdrawal in Vascular Composite Tissue Allotransplantation. <i>American Journal of Transplantation</i> , 2015, 15, 1421-1431.	2.6	45
143	BK polyomavirus reactivation after reduced-intensity double umbilical cord blood cell transplantation. <i>Transplant Immunology</i> , 2015, 32, 116-120.	0.6	7
144	Serious Infections Among Adult Medicaid Beneficiaries With Systemic Lupus Erythematosus and Lupus Nephritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 1577-1585.	2.9	177

#	ARTICLE	IF	CITATIONS
145	Invasive Fusariosis in the Voriconazole Era: Single-Center 13-Year Experience. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv099.	0.4	53
146	<i>Pneumocystis jirovecii</i> pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 359-367.	1.1	34
147	824An Open-Label Phase 3 Study of Isavuconazole (VITAL): Focus on Mucormycosis. <i>Open Forum Infectious Diseases</i> , 2014, 1, S235-S236.	0.4	13
148	825A Phase 3, Randomized, Double-Blind, Non-Inferiority Trial to Evaluate Efficacy and Safety of Isavuconazole vs Voriconazole in Patients with Invasive Mold Disease (IMD): Outcomes in Patients with Pulmonary Infections. <i>Open Forum Infectious Diseases</i> , 2014, 1, S236-S236.	0.4	1
149	The Management of Antibody-Mediated Rejection in the First Presensitized Recipient of a Full-Face Allograft. <i>American Journal of Transplantation</i> , 2014, 14, 1446-1452.	2.6	97
150	<scp>DAS</scp>181 treatment of hematopoietic stem cell transplant patients with parainfluenza virus lung disease requiring mechanical ventilation. <i>Transplant Infectious Disease</i> , 2014, 16, 141-144.	0.7	41
151	Clinical characteristics and outcomes of clostridial bacteraemia in cancer patients. <i>Clinical Microbiology and Infection</i> , 2014, 20, 752-757.	2.8	5
152	Serologic Response to Hepatitis B Vaccination Among Lung Transplantation Candidates. <i>Transplantation</i> , 2014, 98, 676-679.	0.5	6
153	Green Herring Syndrome: Bacterial Infection in Patients With Mucormycosis Cavitory Lung Disease. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu014.	0.4	5
154	Isavuconazole Treatment of a Patient with Disseminated Mucormycosis. <i>Journal of Clinical Microbiology</i> , 2014, 52, 1016-1019.	1.8	60
155	Safety and Pharmacokinetics of Intravenous Zanamivir Treatment in Hospitalized Adults With Influenza: An Open-label, Multicenter, Single-Arm, Phase II Study. <i>Journal of Infectious Diseases</i> , 2014, 209, 542-550.	1.9	51
156	Live Attenuated Varicella-Zoster Vaccine in Hematopoietic Stem Cell Transplantation Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 285-287.	2.0	51
157	Adjunctive management of central line-associated bloodstream infections with 70% ethanol-lock therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1665-1668.	1.3	11
158	Long-Term Stability at $\sim 20^{\circ}\text{C}$ of Aspergillus Galactomannan in Serum and Bronchoalveolar Lavage Specimens. <i>Journal of Clinical Microbiology</i> , 2014, 52, 2108-2111.	1.8	15
159	A Breath Fungal Secondary Metabolite Signature to Diagnose Invasive Aspergillosis. <i>Clinical Infectious Diseases</i> , 2014, 59, 1733-1740.	2.9	129
160	Incidence and risk factors for herpes zoster following heart transplantation. <i>Transplant Infectious Disease</i> , 2014, 16, 17-25.	0.7	45
161	Triple opportunistic pulmonary cavitory disease after cord blood transplantation. <i>Transplant Infectious Disease</i> , 2014, 16, 818-821.	0.7	2
162	The polyomavirus puzzle: is host immune response beneficial in controlling <scp>BK</scp> virus after adult hematopoietic cell transplantation?. <i>Transplant Infectious Disease</i> , 2014, 16, 521-531.	0.7	17

#	ARTICLE	IF	CITATIONS
163	Reply to "Insufficient Demonstration of Long-Term Stability of Aspergillus Galactomannan". Journal of Clinical Microbiology, 2014, 52, 4119-4119.	1.8	3
164	BK Virus Disease after Allogeneic Stem Cell Transplantation: A Cohort Analysis. Biology of Blood and Marrow Transplantation, 2014, 20, 564-570.	2.0	61
165	Cefepime vs Other Antibacterial Agents for the Treatment of Enterobacter Species Bacteremia. Clinical Infectious Diseases, 2014, 58, 1554-1563.	2.9	75
166	Cost analysis of dental services needed before hematopoietic cell transplantation. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2014, 117, 59-66.	0.2	8
167	Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell Transplantation. Annals of Internal Medicine, 2014, 161, 319.	2.0	370
168	Sociodemographics and epidemiology of serious infections requiring hospitalization among adults with systemic lupus erythematosus and lupus nephritis, 2000 to 2006. Arthritis Research and Therapy, 2014, 16, A37.	1.6	0
169	A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. Blood, 2014, 124, 2921-2929.	0.6	145
170	Primary Treatment of Invasive Mucormycosis (IM) with Isavuconazole (VITAL Study) or Amphotericin Formulations (FungiScope,®): Case Matched Analysis. Blood, 2014, 124, 1151-1151.	0.6	1
171	Sequence-Based Discovery of <i>Bradyrhizobium enterica</i> in Cord Colitis Syndrome. New England Journal of Medicine, 2013, 369, 517-528.	13.9	148
172	Cytomegalovirus disease in lung transplantation: impact of recipient seropositivity and duration of antiviral prophylaxis. Transplant Infectious Disease, 2013, 15, 163-170.	0.7	28
173	Vascularized composite tissue allotransplantation – state of the art. Clinical Transplantation, 2013, 27, 330-337.	0.8	66
174	Sequence-Based Discovery of Novel Bacteria, <i>Bradyrhizobium Enterica</i> , in Cord Colitis Syndrome. Biology of Blood and Marrow Transplantation, 2013, 19, S281-S282.	2.0	0
175	One-Year Safety and Immunogenicity of Two Formulations of an Adjuvanted Varicella-Zoster Virus (VZV) Subunit Candidate Vaccine in Adult Autologous Hematopoietic Cell Transplant (HCT) Recipients. Biology of Blood and Marrow Transplantation, 2013, 19, S168-S169.	2.0	2
176	Postoperative Antibacterial Prophylaxis for the Prevention of Infectious Complications Associated With Tube Thoracostomy in Patients Undergoing Elective General Thoracic Surgery. JAMA Surgery, 2013, 148, 440.	2.2	33
177	Ask, Don't Tell – Mobile Phones to Improve HIV Care. New England Journal of Medicine, 2013, 369, 1867-1868.	13.9	36
178	<i>Bradyrhizobium enterica</i> in Cord Colitis Syndrome. New England Journal of Medicine, 2013, 369, 1866-1867.	13.9	16
179	Fatal adenovirus encephalomyeloradiculitis in an umbilical cord stem cell transplant recipient. Neurology, 2013, 80, 1715-1717.	1.5	16
180	Neutropenia Associated With Prolonged Daptomycin Use: Table 1.. Clinical Infectious Diseases, 2013, 56, 1353-1354.	2.9	6

#	ARTICLE	IF	CITATIONS
181	CMX001 to Prevent Cytomegalovirus Disease in Hematopoietic-Cell Transplantation. <i>New England Journal of Medicine</i> , 2013, 369, 1227-1236.	13.9	336
182	Infections Following Facial Composite Tissue Allotransplantation-Single Center Experience and Review of the Literature. <i>American Journal of Transplantation</i> , 2013, 13, 770-779.	2.6	42
183	Respiratory Virus Detection in Immunocompromised Patients with FilmArray Respiratory Panel Compared to Conventional Methods. <i>Journal of Clinical Microbiology</i> , 2012, 50, 3216-3221.	1.8	68
184	Serum Galactomannan and (1 α '3)- β -D-Glucan Assays for Patients with Multiple Myeloma and Waldenstrom's Macroglobulinemia. <i>Journal of Clinical Microbiology</i> , 2012, 50, 1054-1056.	1.8	5
185	A Targeted Peritransplant Antifungal Strategy for the Prevention of Invasive Fungal Disease After Lung Transplantation. <i>Transplantation</i> , 2012, 94, 281-286.	0.5	36
186	Cord-Blood Hematopoietic Stem Cell Transplant Confers an Increased Risk for Human Herpesvirus-6-Associated Acute Limbic Encephalitis: A Cohort Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1638-1648.	2.0	141
187	Safety of Posaconazole and Sirolimus Coadministration in Allogeneic Hematopoietic Stem Cell Transplants. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1462-1465.	2.0	25
188	Invasive <i>Mycobacterium</i> fungal cellulitis and myositis. <i>Medical Mycology</i> , 2012, 50, 740-745.	0.3	6
189	Post-diagnostic kinetics of the (1 α ' 3)- β -d-glucan assay in invasive aspergillosis, invasive candidiasis and <i>Pneumocystis jirovecii</i> pneumonia. <i>Clinical Microbiology and Infection</i> , 2012, 18, E122-E127.	2.8	53
190	CMX001 for Prevention and Control of CMV Infection in CMV-Seropositive Allogeneic Stem-Cell Transplant Recipients: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial of Safety, Tolerability and Antiviral Activity. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, S203-S204.	2.0	9
191	Three Patients with Full Facial Transplantation. <i>New England Journal of Medicine</i> , 2012, 366, 715-722.	13.9	230
192	Clinical potential of DAS181 for treatment of parainfluenza A infections in transplant recipients. <i>Transplant Infectious Disease</i> , 2012, 14, 427-433.	0.7	58
193	Non-tuberculous mycobacterial infection among lung transplant recipients: a 15-year cohort study. <i>Transplant Infectious Disease</i> , 2012, 14, 452-460.	0.7	112
194	BK Virus Disease Following Allogeneic Stem Cell Transplantation: A Cohort Analysis. <i>Blood</i> , 2012, 120, 1927-1927.	0.6	0
195	BK Virus Reactivation After Double Umbilical Cord Blood Transplantation in Adults Correlates with Tregs and Delayed Reconstitution of CD4+ and CD8+ T Effector Cells. <i>Blood</i> , 2012, 120, 4174-4174.	0.6	0
196	Next-Generation Sequencing for the Identification of Transplantation-Associated Pathogens. <i>Blood</i> , 2012, 120, LBA-4-LBA-4.	0.6	1
197	Maribavir and human cytomegalovirus: what happened in the clinical trials and why might the drug have failed?. <i>Current Opinion in Virology</i> , 2011, 1, 555-562.	2.6	81
198	Infectious Complications Associated with Immunomodulating Biologic Agents. <i>Hematology/Oncology Clinics of North America</i> , 2011, 25, 117-138.	0.9	34

#	ARTICLE	IF	CITATIONS
199	How Do We Manage Oral Infections in Allogeneic Stem Cell Transplantation and Other Severely Immunocompromised Patients?. Oral and Maxillofacial Surgery Clinics of North America, 2011, 23, 579-599.	0.4	15
200	Seroprotective Titers against 2009 H1N1 Influenza A Virus after Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Recipients. Biology of Blood and Marrow Transplantation, 2011, 17, 434-438.	2.0	66
201	Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infectious Diseases, The, 2011, 11, 284-292.	4.6	315
202	Thriving On Steroids: An Unexpected Case Of Disseminated Strongyloidiasis. , 2011, , .		0
203	Pandemic H1N1 Influenza Infection in Adult Transplant Recipients. Transplantation, 2011, 91, e80-e81.	0.5	5
204	HIV-1 and 2009 H1N1 Influenza A in Adults. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, e111-e113.	0.9	1
205	Cerebral phaeohyphomycosis caused by <i>Bipolaris spicifera</i> after heart transplantation. Transplant Infectious Disease, 2011, 13, 419-423.	0.7	25
206	Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease. Mycoses, 2011, 54, e838-e847.	1.8	18
207	Cord Colitis Syndrome in Cord-Blood Stem-Cell Transplantation. New England Journal of Medicine, 2011, 365, 815-824.	13.9	103
208	Elevated Serum Beta-d-Glucan Levels in Immunocompromised Children with Clinical Suspicion for Pneumocystis jirovecii Pneumonia. Vaccine Journal, 2011, 18, 1202-1203.	3.2	5
209	Molecular Methods To Improve Diagnosis and Identification of Mucormycosis. Journal of Clinical Microbiology, 2011, 49, 2151-2153.	1.8	162
210	Gordonia bronchialis Bacteremia and Pleural Infection: Case Report and Review of the Literature. Journal of Clinical Microbiology, 2011, 49, 1662-1666.	1.8	42
211	Invasive Fungal Disease after Remote Inoculation in Transplant Recipients. Clinical Infectious Diseases, 2011, 52, e7-e10.	2.9	8
212	Mortality in Hematologic Malignancy and Hematopoietic Stem Cell Transplant Patients with Mucormycosis, 2001 to 2009. Antimicrobial Agents and Chemotherapy, 2011, 55, 5018-5021.	1.4	39
213	Treatment of Parainfluenza 3 Infection With DAS181 in a Patient After Allogeneic Stem Cell Transplantation. Clinical Infectious Diseases, 2011, 53, e77-e80.	2.9	56
214	HHV-6-Associated Post-Transplantation Acute Limbic Encephalitis Following Cord Blood Stem Cell Transplantation: A Cohort Analysis. Blood, 2011, 118, 649-649.	0.6	0
215	Pre-Emptive Rituximab for the Prevention of EBV-Related PTLD in Umbilical Cord Blood Transplantation Patients. Blood, 2011, 118, 3031-3031.	0.6	0
216	Transplant infectious disease as a subspecialty: does outlining how we train define who we are?. Transplant Infectious Disease, 2010, 12, 187-189.	0.7	1

#	ARTICLE	IF	CITATIONS
217	Infectious Granulomatous Dermatitis Associated With <i>Rothia mucilaginosa</i> Bacteremia: A Case Report. <i>American Journal of Dermatopathology</i> , 2010, 32, 175-179.	0.3	18
218	Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: A retrospective, observational, sequential cohort analysis. <i>Clinical Therapeutics</i> , 2010, 32, 637-648.	1.1	56
219	Invasive fungal disease in patients treated for newly diagnosed acute leukemia. <i>American Journal of Hematology</i> , 2010, 85, 695-699.	2.0	60
220	Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. <i>Transplant Infectious Disease</i> , 2010, 12, 489-496.	0.7	116
221	Xenotropic Murine Leukemia Virus-Related Virus Prevalence in Patients with Chronic Fatigue Syndrome or Chronic Immunomodulatory Conditions. <i>Journal of Infectious Diseases</i> , 2010, 202, 1478-1481.	1.9	60
222	Candidaemia associated with decreased in vitro fluconazole susceptibility: is <i>Candida</i> speciation predictive of the susceptibility pattern?. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1460-1465.	1.3	84
223	Prognostic Features of Galactomannan Antigenemia in Galactomannan-Positive Invasive Aspergillosis. <i>Journal of Clinical Microbiology</i> , 2010, 48, 1255-1260.	1.8	82
224	Prognostic Features of Galactomannan Antigenemia in Galactomannan-Positive Invasive Aspergillosis. <i>Journal of Clinical Microbiology</i> , 2010, 48, 1994-1994.	1.8	1
225	Disseminated dermatophytosis in a patient with hereditary hemochromatosis and hepatic cirrhosis: case report and review of the literature. <i>Medical Mycology</i> , 2010, 48, 518-527.	0.3	75
226	Infectious Complications Associated with Immunomodulating Biologic Agents. <i>Infectious Disease Clinics of North America</i> , 2010, 24, 285-306.	1.9	78
227	<i>Fonsecaea monophora</i> cerebral phaeohyphomycosis: case report of successful surgical excision and voriconazole treatment and review. <i>Medical Mycology</i> , 2010, 48, 769-774.	0.3	39
228	Cord Colitis: An Antibiotic-Responsive Colitis Syndrome Following Cord Blood Stem Cell Transplantation. <i>Blood</i> , 2010, 116, 1270-1270.	0.6	0
229	Positively false. <i>Journal of Hospital Medicine</i> , 2009, 4, 194-199.	0.7	0
230	<i>Strongyloides</i> hyperinfection syndrome and transplantation: a preventable, frequently fatal infection. <i>Transplant Infectious Disease</i> , 2009, 11, 97-99.	0.7	18
231	Disseminated <i>Geotrichum candidum</i> infection in a patient with relapsed acute myelogenous leukemia following allogeneic stem cell transplantation and review of the literature. <i>Transplant Infectious Disease</i> , 2009, 11, 458-462.	0.7	44
232	Hepatitis B Virus Reactivation following Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1049-1059.	2.0	138
233	Diagnostic Efficacy and Safety of Computed Tomography-Guided Transthoracic Needle Biopsy in Patients with Hematologic Malignancies. <i>Academic Radiology</i> , 2009, 16, 1408-1415.	1.3	17
234	Diagnostic Performance of the (1-3)- β -D-Glucan Assay for Invasive Fungal Disease. <i>Clinical Infectious Diseases</i> , 2009, 49, 1650-1659.	2.9	204

#	ARTICLE	IF	CITATIONS
235	Role of (1 α) ³ - β -D-glucan in the diagnosis of invasive aspergillosis. <i>Medical Mycology</i> , 2009, 47, S233-S240.	0.3	123
236	Adenovirus Infections in Patients Undergoing Umbilical Cord Blood Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2009, 114, 1132-1132.	0.6	0
237	Human herpesvirus 6 encephalitis. <i>Current Infectious Disease Reports</i> , 2008, 10, 292-9.	1.3	38
238	Management of Oral Infections in Cancer Patients. <i>Dental Clinics of North America</i> , 2008, 52, 129-153.	0.8	31
239	Persistent and Relapsing Babesiosis in Immunocompromised Patients. <i>Clinical Infectious Diseases</i> , 2008, 46, 370-376.	2.9	299
240	POST-TRANSPLANT ACUTE LIMBIC ENCEPHALITIS: CLINICAL FEATURES AND RELATIONSHIP TO HHV6. <i>Neurology</i> , 2008, 70, 491-493.	1.5	20
241	Recovery of <i>Herbaspirillum</i> Species from Persons with Cystic Fibrosis. <i>Journal of Clinical Microbiology</i> , 2008, 46, 2774-2777.	1.8	53
242	Infection in the Hematopoietic Stem Cell Transplant Recipient. , 2008, , 421-448.		4
243	Posaconazole for Invasive Aspergillosis?. <i>Clinical Infectious Diseases</i> , 2007, 45, 664-664.	2.9	2
244	Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. <i>Blood</i> , 2007, 110, 490-500.	0.6	136
245	Post-transplant acute limbic encephalitis. <i>Neurology</i> , 2007, 69, 156-165.	1.5	268
246	(1 α) ³ - β -D-Glucan Assay Positivity in Patients with <i>Pneumocystis (carinii) jirovecii</i> Pneumonia. <i>Annals of Internal Medicine</i> , 2007, 147, 70.	2.0	83
247	Torsades de pointes associated with voriconazole use. <i>Transplant Infectious Disease</i> , 2007, 9, 33-36.	0.7	55
248	Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study. <i>Transplant Infectious Disease</i> , 2007, 9, 121-125.	0.7	81
249	Treatment of Cavitory Pulmonary Zygomycosis With Surgical Resection and Posaconazole. <i>Annals of Thoracic Surgery</i> , 2006, 82, 338-340.	0.7	15
250	Voriconazole and Sirolimus Coadministration after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 552-559.	2.0	102
251	The prevention of infection post-transplant: the role of prophylaxis, preemptive and empiric therapy. <i>Transplant International</i> , 2006, 19, 2-11.	0.8	54
252	The persistent challenges of bacterial infections in the transplant recipient. <i>Transplant Infectious Disease</i> , 2006, 8, 125-127.	0.7	4

#	ARTICLE	IF	CITATIONS
253	Transmission of Lymphocytic Choriomeningitis Virus by Organ Transplantation. <i>New England Journal of Medicine</i> , 2006, 354, 2235-2249.	13.9	491
254	Reactivity of (1 α) ³ - β -D-Glucan Assay with Commonly Used Intravenous Antimicrobials. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3450-3453.	1.4	136
255	Infectious Complications Associated with Alemtuzumab Use for Lymphoproliferative Disorders. <i>Clinical Infectious Diseases</i> , 2006, 43, 16-24.	2.9	255
256	Emergence of a Clinical Daptomycin-Resistant <i>Staphylococcus aureus</i> Isolate during Treatment of Methicillin-Resistant <i>Staphylococcus aureus</i> Bacteremia and Osteomyelitis. <i>Journal of Clinical Microbiology</i> , 2006, 44, 595-597.	1.8	178
257	Risk of HHV6-Associated Post-Transplant Acute Limbic Encephalitis (PALE) after Umbilical Cord Blood Stem Cell Transplantation: A Cohort Analysis. <i>Blood</i> , 2006, 108, 2929-2929.	0.6	1
258	Myiasis Due to <i>Dermatobia hominis</i> (Human Botfly). <i>New England Journal of Medicine</i> , 2005, 352, e21.	13.9	14
259	Lyme Meningoradiculitis and Myositis after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2005, 41, e112-e114.	2.9	10
260	Treatment of Human Disseminated Strongyloidiasis with a Parenteral Veterinary Formulation of Ivermectin. <i>Clinical Infectious Diseases</i> , 2005, 41, e5-e8.	2.9	96
261	Breakthrough Zygomycosis after Voriconazole Treatment in Recipients of Hematopoietic Stem-Cell Transplants. <i>New England Journal of Medicine</i> , 2004, 350, 950-952.	13.9	412
262	Principles of antimicrobial therapy in the transplant patient. <i>Transplant Infectious Disease</i> , 2004, 6, 97-100.	0.7	11
263	Disseminated Trichosporonosis Caused by <i>Trichosporon loubieri</i> . <i>Journal of Clinical Microbiology</i> , 2003, 41, 5317-5320.	1.8	52
264	Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. <i>Blood</i> , 2003, 102, 2768-2776.	0.6	196
265	Antifungal use in HIV infection. <i>Expert Opinion on Pharmacotherapy</i> , 2002, 3, 91-102.	0.9	37
266	Neurosyphilis Presenting as Herpes Simplex Encephalitis. <i>Clinical Infectious Diseases</i> , 2001, 32, 1108-1109.	2.9	31
267	The relationship between antibiotic agent and mortality in patients with febrile neutropenia due to Staphylococcal bloodstream infection: a multicenter cohort study. <i>Open Forum Infectious Diseases</i> , 0, , .	0.4	1